The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ranibizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS: In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab. CONCLUSIONS: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of anti-VEGF agent, pre-treatment ADA titers have not been shown to have any clinically relevant difference in BCVA outcomes [30, 33, 41, 43].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Repeated intravitreal (IVT) injections of anti-VEGF therapies effectively slow vision loss in the majority of treatment-compliant patients with wet AMD. 7 – 13”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this initial response at month 4 is not always predictive of long-term VA gains, as a proportion of such eyes continue to accrue gains in vision even after month 4 as in the ANCHOR and MARINA studies, 22,24 HARBOR study 30 and subsequent case series.31”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other major anti-VEGF clinical trials excluded such patients.18,19,20”
From Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials (2018) · cites this paper as [19]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, such lesions may be difficult to categorise as there are a group of 'delayed responders' who will not gain vision until well after 3 and sometimes not until after 12 months.22,24”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [1]
In the citing paper
“was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Ranibizumab is a fragment of a monoclonal antibody that binds to and inhibits all forms of VEGF-A.164,165”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“This drug, when injected intravitreally on a monthly basis, prevented vision loss”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“These benefits persisted through 24 months of follow-up.”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Mean differences in visual acuity score in the treated and control groups were also impressive, with a mean increase of seven letters in the treated group compared with a mean decrease of 10 letters in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“At 12 months, 95% of patients given ranibizumab 0·5 mg lost fewer than 15 letters (three lines of vision) compared with 62% of the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“for the first time with any treatment for age-related macular degeneration, was associated with a remarkable proportion of patients with an improvement in vision”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“Additionally, 34% of this group improved by 15 or more letters of vision compared with the 5% in the placebo group (p<0·001).”
From Age-related macular degeneration (2008) · cites this paper as [164]
In the citing paper
“The adverse effects included endophthalmitis (1%) and serious uveitis (1%).”
From Age-related macular degeneration (2008) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,788
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationAltman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,774
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Flagged first, then by citations
Research works printed but not linked: 5
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
- Lopez PF, 1996, Invest Ophthalmol Vis Sci, 37, 855
- Kvanta A, 1996, Invest Ophthalmol Vis Sci, 37, 1929
- Grading of vitreous cells. In: Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. 2nd ed. New York: Mosby, 1996:64.
Cited by
Sorted by citations
Items 201–300 of 1,051
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
Retinal Precursors and the Development of Geographic Atrophy in Age-Related Macular Degeneration
Klein, M. L., Ferris, F. L., Armstrong, J., Hwang, T. S., Chew, E. Y., Bressler, S. B., & Chandra, S. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.08.030 · Cited by 224
Willoughby, A. S., Ying, G., Toth, C. A., Maguire, M. G., Burns, R. E., Grunwald, J. E., Daniel, E., Jaffe, G. J., Williams, D. F., Beardsley, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.042 · Cited by 224
Chong, E. W. T., Wong, T. Y., Kreis, A., Simpson, J. A., & Guymer, R. H. (2007) · BMJ · doi:10.1136/bmj.39350.500428.47 · Cited by 223
Whitmore, S. S., Sohn, E. H., Chirco, K. R., Drack, A. V., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.005 · Cited by 223
Brown, D. M., & Regillo, C. D. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.039 · Cited by 223
Self-citationRanibizumab in neovascular age-related macular degeneration
Eng, K. T., & Kertes, P. J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.451 · Cited by 222
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F. M., Navarra, P., Staurenghi, G., Stumpp, M. T., & Zarbin, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 224
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature
Shen, J., Frye, M., Lee, B. L., Reinardy, J. L., McClung, J. M., Ding, K., Kojima, M., Xia, H., Seidel, C. P., Silva, R. L. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74527 · Cited by 220
Kaiser, P. K., Blodi, B. A., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.04.030 · Cited by 219
Self-citationAvery, R. L., & Gordon, G. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4070 · Cited by 218
Phototoxic aptamers selectively enter and kill epithelial cancer cells
Ferreira, C. S. M., Cheung, M. C., Missailidis, S., Bisland, S. K., & Gariépy, J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn967 · Cited by 216
MicroRNAs Regulate Ocular Neovascularization
Shen, J., Yang, X., Xie, B., Chen, Y., Swaim, M., Hackett, S. F., & Campochiaro, P. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.104 · Cited by 216
INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
Fintak, D. R., Shah, G. K., Blinder, K. J., Regillo, C. D., Pollack, J. S., Heier, J. S., Hollands, H., & Sharma, S. (2008) · Retina · doi:10.1097/iae.0b013e3181884fd2 · Cited by 215
Self-citationTufail, A., Patel, P. J., Egan, C. A., Hykin, P. G., da Cruz, L., Gregor, Z. J., Dowler, J. G. F., Majid, M. A., Bailey, C., Mohamed, Q. A., et al. (2010) · BMJ · doi:10.1136/bmj.c2459 · Cited by 215
Neovascular Age-Related Macular Degeneration
Chappelow, A. V., & Kaiser, P. K. (2008) · Drugs · doi:10.2165/00003495-200868080-00002 · Cited by 214
Self-citationOrozco, L. D., Chen, H.-H., Cox, C., Katschke, K. J., Arceo, R., Espiritu, C., Caplazi, P., Nghiem, S. S., Chen, Y., Modrusan, Z. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.082 · Cited by 214
Stem cell based therapies for age-related macular degeneration: The promises and the challenges
Nazari, H. K., Zhang, L., Zhu, D., Chader, G. J., Falabella, P., Stefanini, F. R., Rowland, T. J., Clegg, D., Kashani, A. H., Hinton, D. R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.004 · Cited by 212
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path ForwardPreprint
Kieran, M. W., Kalluri, R., & Cho, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006593 · Cited by 212
Schmidt-Erfurth, U., Waldstein, S. M., Deak, G.-G., Kundi, M., & Simader, C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.017 · Cited by 211
Pseudoxanthoma Elasticum: Genetics, Clinical Manifestations and Therapeutic Approaches
Finger, R. P., Issa, P. C., Ladewig, M. S., Götting, C., Szliska, C., Scholl, H. P. N., & Holz, F. G. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.12.006 · Cited by 211
Bhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.032 · Cited by 210
Self-citationSubthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration
Guymer, R. H., Wu, Z., Hodgson, L., Caruso, E., Brassington, K. H., Tindill, N., Aung, K. Z., McGuinness, M. B., Fletcher, E. L., Chen, F. K., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.09.015 · Cited by 210
Schaal, S., Kaplan, H. J., & Tezel, T. H. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.07.007 · Cited by 209
Interventions for Central Retinal Vein Occlusion
Mohamed, Q. A., McIntosh, R. L., Saw, S., & Wong, T. Y. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.11.011 · Cited by 208
Xu, L., Lu, T., Tuomi, L., Jumbe, N. L. ‘., Lü, J., Eppler, S., Kuebler, P., Damico‐Beyer, L. A., & Joshi, A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10260 · Cited by 208
Recent developments in the treatment of age-related macular degeneration
Holz, F. G., Schmitz-Valckenberg, S., & Fleckenstein, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71029 · Cited by 207
Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G., Maguire, M. G., Daniel, E., & Martín, D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 207
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 206
Current update on retinopathy of prematurity: screening and treatment
Chen, J., Stahl, A., Hellström, A., & Smith, L. E. H. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283423f35 · Cited by 206
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration
Moshfeghi, A. A., Rosenfeld, P. J., Puliafito, C. A., Michels, S., Marcus, E. N., Lenchus, J. D., & Venkatraman, A. S. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.070 · Cited by 206
Self-citationRoles of VEGF-A signalling in development, regeneration, and tumours
Matsumoto, K., & Ema, M. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu031 · Cited by 206
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
Stewart, M. W. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.10.001 · Cited by 206
Ciulla, T. A., Hussain, R. M., Pollack, J. S., & Williams, D. F. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.017 · Cited by 205
Ho, L. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.141 · Cited by 204
Cohen, S. Y., Mimoun, G., Oubraham, H., Zourdani, A., Malbrel, C., Quéré, S., & Schneider, V. (2012) · Retina · doi:10.1097/iae.0b013e31827b6324 · Cited by 204
The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market
Titze‐de‐Almeida, R., David, C., & Titze-de-Almeida, S. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2134-2 · Cited by 203
Chen, X., Niemeijer, M., Zhang, L., Lee, K., Abràmoff, M. D., & Milan Sonka, A. (2012) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2012.2191302 · Cited by 202
Schmidt-Erfurth, U. M., Bogunović, H., Sadeghipour, A., Schlegl, T., Langs, G., Gerendas, B. S., Osborne, A. R., & Waldstein, S. M. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.015 · Cited by 201
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Schmitz-Valckenberg, S., Brinkmann, C. K., Alten, F., Herrmann, P., Stratmann, N. K., Göbel, A. P., Fleckenstein, M., Diller, M., Jaffe, G. J., & Holz, F. G. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7457 · Cited by 197
Chew, E. Y., Clemons, T. E., Bressler, S. B., Elman, M. J., Danis, R. P., Domalpally, A., Heier, J. S., Kim, J. E., & Garfinkel, R. A. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.027 · Cited by 196
Self-citationPrenner, J. L., Halperin, L. S., Rycroft, C. E., Hogue, S., Liu, Z. W., & Seibert, R. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.023 · Cited by 195
Jung, J. J., Chen, C. Y., Mrejen, S., Gallego‐Pinazo, R., Xu, L., Marsiglia, M., Boddu, S., & Freund, K. B. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.006 · Cited by 195
Disorders of Vascular Permeability
Park‐Windhol, C., & D'Amore, P. A. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044506 · Cited by 194
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer
Zhang, G., Kodani, S. D., & Hammock, B. D. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.11.003 · Cited by 193
Engelbert, M., Zweifel, S. A., & Freund, K. B. (2009) · Retina · doi:10.1097/iae.0b013e3181bfbd46 · Cited by 193
Yaspan, B. L., Williams, D. F., Holz, F. G., Regillo, C. D., Li, Z., Dressen, A., Campagne, M. V. L., Le, K. N., Graham, R., Beres, T., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1443 · Cited by 193
Khanani, A. M., Aziz, A. A., Khan, H., Gupta, A. B., Mojumder, O., Saulebayeva, A., Abbey, A. M., Almeida, D. R. P., Avery, R. L., Banda, H. K., et al. (2023) · Eye · doi:10.1038/s41433-023-02553-5 · Cited by 193
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 192
Curtis, L. H. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.223 · Cited by 192
Retinal Vein Occlusion: Beyond the Acute Event
Ehlers, J. P., & Fekrat, S. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.11.006 · Cited by 192
Krebs, I., Schmetterer, L. F., Boltz, A., Told, R., Vécsei-Marlovits, V. P., Egger, S. F., Schönherr, U., Haas, A., Ansari‐Shahrezaei, S., & Binder, S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302391 · Cited by 191
Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis
Geretti, E., Shimizu, A., & Klagsbrun, M. (2008) · Angiogenesis · doi:10.1007/s10456-008-9097-1 · Cited by 191
Antoszyk, A. N., Tuomi, L., Chung, C. Y., & Singh, A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.029 · Cited by 190
Self-citationRakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189
Ocular Associations of Diabetes Other Than Diabetic Retinopathy
Jeganathan, V. S. E., Wang, J. J., & Wong, T. Y. (2008) · Diabetes Care · doi:10.2337/dc08-0342 · Cited by 189
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186
Holz, F. G., Dugel, P. U., Weissgerber, G., Hamilton, R., Silva, R., Bandello, F., Larsen, M., Weichselberger, A., Wenzel, A., Schmidt, A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.030 · Cited by 184
Dossarps, D., Bron, A. M., Koehrer, P., Aho-Glélé, L. S., Creuzot-Garcher, C., Berthon, L., Maftouhi, Q.-E., Bakhti, A., Conrath, J., Le Mer, Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.013 · Cited by 184
Comparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis
Hammersmith, K. M., & Nagra, P. K. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.102 · Cited by 184
Kim, L. N., Mehta, H., Barthelmes, D., Nguyen, V., & Gillies, M. C. (2016) · Retina · doi:10.1097/iae.0000000000001142 · Cited by 184
Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia
Ohno‐Matsui, K., Ikuno, Y., Lai, T. Y. Y., & Cheung, C. M. G. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.005 · Cited by 184
Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration
Merle, B. M. J., Colijn, J. M., Cougnard-Grégoire, A., de Koning-Backus, A. P. M., Delyfer, M., Jong, J. C. K., Meester-Smoor, M., Féart, C., Verzijden, T., Samieri, C., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.006 · Cited by 184
Oxidation and age-related macular degeneration: insights from molecular biology
Khandhadia, S., & Lotery, A. J. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941000164x · Cited by 183
Vascular endothelial growth factor biology: clinical implications for ocular treatments
Bhisitkul, R. B. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098426 · Cited by 182
ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS
Moshfeghi, A. A., Rosenfeld, P. J., Flynn, H. W., Schwartz, S. G., Davis, J. L., Murray, T. G., Smiddy, W. E., Berrocal, A. M., Dubovy, S. R., Lee, W., et al. (2011) · Retina · doi:10.1097/iae.0b013e31821067c4 · Cited by 182
Self-citationKumar, N., Marsiglia, M., Mrejen, S., Fung, A. T.-C., Slakter, J. S., Sorenson, J. A., & Freund, K. B. (2013) · Retina · doi:10.1097/iae.0b013e31828e8551 · Cited by 181
Pilli, S., Kotsolis, A. I., Spaide, R. F., Slakter, J. S., Freund, K. B., Sorenson, J. A., Klancnik, J. M., & Cooney, M. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.036 · Cited by 181
Augood, C. A., Chakravarthy, U., Young, I. S., Vioqué, J., de Jong, P. T. V. M., Bentham, G., Rahu, M., Seland, J. H., Soubrane, G., Tomazzoli, L., et al. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.398 · Cited by 181
Lanzetta, P., & Loewenstein, A. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3647-4 · Cited by 181
Age‐related macular degeneration—clinical review and genetics update
Ratnapriya, R., & Chew, E. Y. (2013) · Clinical Genetics · doi:10.1111/cge.12206 · Cited by 180
Functional Cone Rescue by RdCVF Protein in a Dominant Model of Retinitis Pigmentosa
Yang, Y., Mohand‐Saïd, S., Danan, A., Simonutti, M., Fontaine, V. K., Clérin, E., Picaud, S. A., Léveillard, T., & Sahel, J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.28 · Cited by 180
Christen, W. G., Glynn, R. J., Chew, E. Y., Albert, C. M., & Manson, J. E. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.574 · Cited by 180
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S. M., & Pascale, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 180
TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
FOROOGHIAN, F., CUKRAS, C., MEYERLE, C. B., CHEW, E. Y., & WONG, W. T. (2009) · Retina · doi:10.1097/iae.0b013e3181a2c1c3 · Cited by 179
MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT
Mrejen, S., Sarraf, D., Mukkamala, S. K., & Freund, K. B. (2013) · Retina · doi:10.1097/iae.0b013e3182993f66 · Cited by 179
Role of the retinal vascular endothelial cell in ocular disease
Bharadwaj, A. S., Appukuttan, B., Wilmarth, P. A., Pan, Y., Stempel, A. J., Chipps, T. J., Benedetti, E., Zamora, D. O., Choi, D., David, L. L., et al. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.08.004 · Cited by 179
Arnold, J., Campain, A. E., Barthelmes, D., Simpson, J. M., Guymer, R. H., Hunyor, A. P., McAllister, I. L., Essex, R. W., Morlet, N., Gillies, M. C., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.009 · Cited by 179
Simader, C., Ritter, M., Bolz, M., Deák, G. G., Sponer, U., Golbaz, I., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.029 · Cited by 179
Binet, F., & Sapieha, P. S. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.010 · Cited by 178
Therapeutic targets in age-related macular disease
Bird, A. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42437 · Cited by 178
Funk, M., Karl, D., Georgopoulos, M., Benesch, T., Sacu, S., Polak, K., Zlabinger, G. J., & Schmidt-Erfurth, U. M. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.039 · Cited by 178
Therapeutic monoclonal antibodies in ophthalmology
Rodrigues, E. B., Farah, M. E., Maia, M., Penha, F. M., Regatieri, C. V., Melo, G. B., Pinheiro, M. M., & Zanetti, C. R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.005 · Cited by 177
Progress on retinal image analysis for age related macular degeneration
Kanagasingam, Y., Bhuiyan, A., Abràmoff, M. D., Smith, R. T., Goldschmidt, L. P., & Wong, T. Y. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.10.002 · Cited by 178
Yamazaki, T., Koizumi, H., Yamagishi, T., & Kinoshita, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.022 · Cited by 176
Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature
Stanescu-Segall, D., Balta, F., & Jackson, T. L. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.004 · Cited by 175
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
Gasperini, J. L., Fawzi, A. A., Khondkaryan, A., Lam, L., Chong, L. P., Eliott, D., Walsh, A. C., Hwang, J., & Sadda, S. R. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.204685 · Cited by 175
Drugs derived from phage display
Nixon, A. E., Sexton, D. J., & Ladner, R. C. (2013) · mAbs · doi:10.4161/mabs.27240 · Cited by 174
Age-related macular degeneration and the complement system
Khandhadia, S., Cipriani, V., Yates, J. R. W., & Lotery, A. J. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.019 · Cited by 174
Targeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives
Ngwa, W. F., Kumar, R., Sridhar, S., Korideck, H., Zygmanski, P., Cormack, R. A., Berbeco, R. I., & Makrigiorgos, G. M. (2014) · Nanomedicine · doi:10.2217/nnm.14.55 · Cited by 173
Sultan, M. B., Zhou, D., Loftus, J., Dombi, T., & Ice, K. S. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.045 · Cited by 173
Waldstein, S. M., Simader, C., Staurenghi, G., Chong, V. N., Mitchell, P., Jaffe, G. J., Lu, C., Katz, T. A., & Schmidt-Erfurth, U. M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.037 · Cited by 173
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 173
Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171
Ennis, S., Jomary, C., Mullins, R., Cree, A., Chen, X., MacLeod, A., Jones, S., Collins, A., Stone, E., & Lotery, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61348-3 · Cited by 171
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170
Metadata
- Authors
- Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y.
- Affiliations
- University of Miami (US)
- Houston Methodist (US)
- Ophthalmic Consultants of Boston (US)
- Retina Vitreous Associates Medical Group (US)
- Cleveland Clinic (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1419-1431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124415048
- Cited by
- 5,886
- References
- 25
- Citations by year
- 2026: 179 · 2025: 231 · 2024: 207 · 2023: 198 · 2022: 242 · 2021: 324 · 2020: 311 · 2019: 259 · 2018: 286 · 2017: 325 · 2016: 313 · 2015: 356 · 2014: 358 · 2013: 371 · 2012: 371
- FWCI
- 240.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Pennsylvania State University
- University of South Florida
- Towson University
- Genentech
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, choroidal neovascularization, intravitreal injection, anti-VEGF therapy, VEGF-A, visual acuity, blindness prevention, endophthalmitis, uveitis, adverse events, long-term follow-up, dose comparison, occult choroidal neovascularization, anti-angiogenic therapy, VEGF inhibitors
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Optic Disk, Visual Acuity, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
